Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by MrMugsyon Apr 25, 2021 9:30am
150 Views
Post# 33063104

RE:RE:RE:RE:RE:Waiting for partnerships ...

RE:RE:RE:RE:RE:Waiting for partnerships ...
Stoxxhp wrote:
WalkOverTheStrt wrote: Mugs -
Antibe doesn't have to take this extreme all or nothing PH3 approach let alone the HS2 platform will not validated if Oten were to pass P3.  The HS2 platform will actually be considered a platform when more than one drug shows success in human trials (even early stage ie PH1 results). One PH3 success will not get it there as there isn't depth of human data to show across multiple studies how HS2 is a safe and consistent molecule. It takes time for BPs to see this as a platform (refer to RNAI - gene silencing hisotry that only became mainstream a few years ago with ALNY's first drug 2017ish). You can't expect a cautious BP to take preclinical data and accept it will pan out that way in human trials. 

This is why I harp on Dan and team for not bringing forth other drugs from the pipeline to human studies earlier. Wallace has been researching HS2 for 20+ years, antibe has had on their corp decks other drugs that have languished. I again point to ARWR as a company that has a platform (TRiM) and decided to accelerate development / human trials in order to make the sum of the whole  (platform) bigger than any indvidual part (drug). 
Realize Antibe is a small biotech and being in CA / TX exchange doesnt help for access real investment but don't you have some reservations why other drugs weren't brought fwd sooner?


I think a basic explanation would be, instead of experimenting with 3 or 4 different drugs at the same time using the same ingredient, they want to confirm with one drug first, once it's proven and legitimized, then they have free rein to expand on a proven concept



And from my understanding, it was a successful P2B that allows us to negotiate with BP and gave us the confidence to pursue the other drugs.  It also opens the door to adding additional drugs to the family.  There's a huge confidence now, even though manangement shouldn't appear too over-confident, the website quotes tell us all we need to know.  Full steam ahead in design and development !
<< Previous
Bullboard Posts
Next >>